← brief for 2026-08-13 · Slowing decline

Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort.

Article C Peer reviewed Observational

Key takeaways

Finerenone use was linked to lower hyperkalemia (high potassium) risk than other mineralocorticoid receptor antagonists. This observational study used data from 1,500 patients with diabetic kidney disease.

Who did this work

Özdede M · Yadigar S · Güven AT · Akgür S · Arslan F · Sezen M · Özcan B · Ayaz EY · Doğantekin B · Atay İ · Değer SM · Demir M

Source

Article · PubMed, the drug frontier · 2026 Jul 6
https://pubmed.ncbi.nlm.nih.gov/42592375/